| Factor Information | |
|---|---|
| Data ID | 2339 |
| Factor | operative vaginal delivery rate |
| Description | 38% had operative vaginal deliveries compared to a 10.5% institution rate (p < 0.01). The comparatively high rate of operative vaginal deliveries in our study (38% compared to the 11% institutional rate) reflects the use of what is often referred to as a ‘cardiac’ delivery (i.e. minimal maternal pushing with operative assistance under dense neuraxial block). |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | a predominance of neuraxial anaesthetic techniques, increased caesarean and operative delivery rates, and favourable maternal and neonatal outcomes. Multicentre studies and registries to compare anaesthetic and obstetric management strategies further and delineate risk factors for adverse outcomes are required. |
| p Value | <0.02 |
| Conclusion | We observed a predominance of neuraxial anaesthetic techniques, increased caesarean and operative delivery rates, and favourable maternal and neonatal outcomes. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 23121251 |
| Year | 2013 |
| Title | Peripartum outcomes and anaesthetic management of parturients with moderate to complex congenital heart disease or pulmonary hypertension |
| Sample | ||
|---|---|---|
| Population | pregnant woman | |
| Source | all pregnancies occurring in women with a diagnosis of moderate to complex congenital cardiac disease during the period from 1 January 2000 to 31 December 2011 at Lucile Packard Children’s Hospital (LPCH), | |
| Region | Stanford, USA | |
| Method | a retrospective cohort analysis | |
| Race | Cucasian/Hispanic/Asian/Black | |
| Disease History | N/A | |
| Treatment History | Neuraxial analgesia or anaesthesia | |
| Group | study cohort(CHD and or PAH)(Treatment) | author's institutional cases(Control) |
| Number | 65 | N/A |
| Age | 30 ± 7 years | N/A |
| Gender (Male: Female) | 0:65 | Female |
| Marker Level | 0.38 | 0.11 |
